Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine
Crossref DOI link: https://doi.org/10.1007/s12402-017-0227-8
Published Online: 2017-05-05
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Thome, Johannes
Dittmann, Ralf W.
Greenhill, Laurence L.
Lipsius, Sarah
Tanaka, Yoko
Bushe, Chris
Escobar, Rodrigo
Heinloth, Alexandra N.
Upadhyaya, Himanshu
Funding for this research was provided by:
Eli Lilly and Company (US)
License valid from 2017-05-05